The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Lucky Bucks, LLC
![flag not available](https://www.greenhill.com/sites/default/files/n_a_flag.gif)
Advised the Term Loan Ad Hoc Group to Lucky Bucks, one of the largest Class B coin operated amusement machine (“COAM”) route operators in Georgia, on Lucky Bucks’ financial restructuring and chapter 11 process
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Slayback Pharma LLC
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Azurity Pharmaceuticals, a pharmaceutical company specializing in the provision of innovative medicines to overlooked patients, on the acquisition of Slayback Pharma LLC ("Slayback"), a company focused on complex generic and specialty pharmaceutical products
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Annovera®, Imvexxy®, Bijuva®, and prescription prenatal vitamin products
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Advised TherapeuticsMD, Inc., an innovative, leading women’s healthcare company on definitive agreements to license its products to Mayne Pharma
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
GI Alliance
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advising the management and majority physician owners of GI Alliance, the largest gastroenterology practice in the United States, on its recapitalization and buyout of minority partner, Waud Capital
![USA/UK U.S.A., U.K. flags](https://www.greenhill.com/sites/default/files/usa_uk.gif)
Acacia Pharma Group plc
![flag not available](https://www.greenhill.com/sites/default/files/n_a_flag.gif)
Advised Acacia Pharma Group plc, a US headquartered commercial stage biopharmaceutical company incorporated in England and listed in Belgium, on its placing of 10m new ordinary shares at a price of €2.70 per share
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
US Acute Care Solutions
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advising US Acute Care Solutions, the largest majority physician-owned emergency medicine practice in the United States, on its recapitalization and buyout of minority partner, Welsh Carson
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Akorn, Inc.
![flag not available](https://www.greenhill.com/sites/default/files/n_a_flag.gif)
Advised Ad Hoc Group of First Lien Term Loan Lenders on Akorn’s in-court recapitalization
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Saga plc
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Advised Sir Roger De Haan on his cornerstone investment of £100mm in Saga, the UK provider of products and services exclusively for the over 50s, as part of its £150m equity raise
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Blue Sky Alternative Investments Limited
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Blue Sky, an ASX-listed diversified alternative assets manager, on its response to an activist short-seller campaign, strategic review of recapitalisation options, and receipt of a A$50mm long-term capital investment by Oaktree via a 7-year senior secured convertible loan note facility
![Canada Canada flag](https://www.greenhill.com/sites/default/files/canada.gif)
Concordia International Corp.
![flag not available](https://www.greenhill.com/sites/default/files/n_a_flag.gif)
Advised an Ad Hoc Group of Cross-over Debtholders on Concordia International’s cross-border Canadian restructuring and recapitalization, including a US$586.5mm common equity private placement, the equitization of ~US$1.7bn of unsecured debt and the partial paydown and exchange of ~US$2.2bn of secured debt
![South Africa/Switzerland South Africa, Switzerland flags](https://www.greenhill.com/sites/default/files/s-africa_switz_91006.gif)
Hirslanden Private Hospital Group
![flag not available](https://www.greenhill.com/sites/default/files/n_a_flag.gif)
Advised Hirslanden Private Hospital Group, Switzerland's largest private hospital group and a wholly-owned subsidiary of Mediclinic International Plc, on the refinancing of its CHF 2.0 billion senior secured bank debt
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Caesars Entertainment
![flag not available](https://www.greenhill.com/sites/default/files/n_a_flag.gif)
Advised selected Second Lien Noteholders, including Canyon Capital Advisors, Mason Capital, Paulson & Co. and Soros Fund Management regarding Caesars Entertainment Operating Company’s Chapter 11 proceedings
![USA/UK U.S.A., U.K. flags](https://www.greenhill.com/sites/default/files/usa_uk.gif)
US rights to Toprol-XL (AstraZeneca)
![Canada Canada flag](https://www.greenhill.com/sites/default/files/canada.gif)
Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the US rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
CPP Group plc
Advised on the comprehensive restructuring of its balance sheet, including sale of the US business, terming out the existing RCF and creation of additional liquidity by the long term deferral of business partner payments
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
A$1.6bn non-core loan portfolio
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Suncorp Group Ltd (ASX:SUN), a leading general insurance, retail banking and life insurance group in Australia and New Zealand, on the sale of a A$1.6bn portfolio of performing and non-performing (corporate and property) loans to Goldman Sachs Group Inc., an American multinational investment banking firm
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
American International Group (AIG)
Advised the United States Department of the Treasury (“UST”) on the full reduction of its 92% ownership stake in the insurer through numerous Secondary Public Offering Transactions
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
The Hartford’s Individual Life Insurance Business
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised The Hartford, a leading provider of insurance and wealth management services, on the divestiture of its Individual Life Insurance Business to Prudential Financial, Inc.
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
The Hartford’s Retirement Plans Group
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised The Hartford, a leading provider of insurance and wealth management services, on the divestiture of its Retirement Plans Group to Massachusetts Mutual Life Insurance Company, a leading mutual life insurance company
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
The Miller Group
Advised The Miller Group, the UK’s largest private homebuilder, on the recapitalization of its balance sheet comprising a substantial new equity capital raising and a significant debt for equity swap
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
ISTA Pharmaceuticals, Inc.
Advised ISTA Pharmaceuticals, an ophthalmic pharmaceutical company, on its defense against an unsolicited offer from Valeant Pharmaceuticals and on its review of strategic alternatives
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Wesco Financial Corporation
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised the Special Committee of Wesco Financial Corporation in connection with Berkshire Hathaway Inc.'s proposal to acquire the remaining 19.9% of the shares of Wesco’s common stock that it does not presently own
![USA/Switzerland U.S.A., Swiss flags](https://www.greenhill.com/sites/default/files/usa_swiss.gif)
Alcon, Inc.
![Switzerland Switzerland flag](https://www.greenhill.com/sites/default/files/switzerland.gif)
Advised the Independent Director Committee of Alcon, Inc., an ophthalmic pharmaceutical company, on the sale of Alcon’s outstanding publicly held interest to Novartis AG, a global pharmaceutical company
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
US Department of the Treasury
Advised the United States Department of the Treasury on the management and disposition of its common shares of AIG
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
General Growth Properties Inc.
Advised the 2006 Credit Facility Lenders, the largest class of unsecured debt with claims in excess of $2.8 billion, in connection with the Chapter 11 proceedings of mall REIT GGP, which resulted in cash payoff of the facilities in full
![UK/Australia U.K., Australia flags](https://www.greenhill.com/sites/default/files/uk_australia.gif)
Guinness Peat Group plc
Advised GPG plc, a listed investment company, on potential restructuring alternatives